Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-207-0202
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$64.87 million
Profitability
Miscellaneous
Employees248
Next Earnings Date8/5/2019 (Estimated)
OptionableOptionable
Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions
What is Akcea Therapeutics' stock symbol?
Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."
How were Akcea Therapeutics' earnings last quarter?
Akcea Therapeutics Inc (NASDAQ:AKCA) released its quarterly earnings data on Wednesday, May, 8th. The company reported $0.34 earnings per share for the quarter, missing analysts' consensus estimates of $1.24 by $0.90. The firm earned $163.82 million during the quarter, compared to analysts' expectations of $171.40 million. Akcea Therapeutics had a negative net margin of 79.88% and a negative return on equity of 54.63%. The firm's quarterly revenue was up 857.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.44) EPS. View Akcea Therapeutics' Earnings History.
When is Akcea Therapeutics' next earnings date?
What price target have analysts set for AKCA?
6 brokers have issued twelve-month price objectives for Akcea Therapeutics' shares. Their forecasts range from $31.00 to $46.00. On average, they expect Akcea Therapeutics' stock price to reach $40.50 in the next year. This suggests a possible upside of 91.0% from the stock's current price. View Analyst Price Targets for Akcea Therapeutics.
What is the consensus analysts' recommendation for Akcea Therapeutics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Akcea Therapeutics.
Has Akcea Therapeutics been receiving favorable news coverage?
Press coverage about AKCA stock has been trending positive recently, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Akcea Therapeutics earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Akcea Therapeutics' key competitors?
Some companies that are related to Akcea Therapeutics include Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO), Marina Biotech (MRNA), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), GALAPAGOS NV/S (GLPG), Array Biopharma (ARRY), Nektar Therapeutics (NKTR), Amarin (AMRN), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND) and Horizon Therapeutics (HZNP).
What other stocks do shareholders of Akcea Therapeutics own?
Who are Akcea Therapeutics' key executives?
Akcea Therapeutics' management team includes the folowing people:
- Ms. Paula Soteropoulos, CEO & Director (Age 51)
- Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
- Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
- Ms. Sarah Boyce, Pres & Director (Age 47)
- Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)
When did Akcea Therapeutics IPO?
(AKCA) raised $125 million in an initial public offering (IPO) on Friday, July 14th 2017. The company issued 9,600,000 shares at a price of $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.
Who are Akcea Therapeutics' major shareholders?
Akcea Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (14.07%), BlackRock Inc. (2.03%), Wellington Management Group LLP (1.20%), Geode Capital Management LLC (0.26%), Northern Trust Corp (0.21%) and Charles Schwab Investment Management Inc. (0.09%). Company insiders that own Akcea Therapeutics stock include Ionis Pharmaceuticals Inc, Jeff Marc Goldberg and Paula Soteropoulos. View Institutional Ownership Trends for Akcea Therapeutics.
Which institutional investors are selling Akcea Therapeutics stock?
AKCA stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, BlackRock Inc., Altrinsic Global Advisors LLC, Schonfeld Strategic Advisors LLC, Wellington Management Group LLP and Parametric Portfolio Associates LLC. Company insiders that have sold Akcea Therapeutics company stock in the last year include Jeff Marc Goldberg and Paula Soteropoulos. View Insider Buying and Selling for Akcea Therapeutics.
Which institutional investors are buying Akcea Therapeutics stock?
AKCA stock was acquired by a variety of institutional investors in the last quarter, including Tibra Equities Europe Ltd, Quantinno Capital Management LP, Citigroup Inc., Wells Fargo & Company MN, Geode Capital Management LLC, Menta Capital LLC, Motley Fool Asset Management LLC and Northern Trust Corp. View Insider Buying and Selling for Akcea Therapeutics.
How do I buy shares of Akcea Therapeutics?
Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Akcea Therapeutics' stock price today?
One share of AKCA stock can currently be purchased for approximately $21.20.
How big of a company is Akcea Therapeutics?
Akcea Therapeutics has a market capitalization of $1.97 billion and generates $64.87 million in revenue each year. The company earns $-225,820,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.
What is Akcea Therapeutics' official website?
How can I contact Akcea Therapeutics?
Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]
MarketBeat Community Rating for Akcea Therapeutics (NASDAQ AKCA)
MarketBeat's community ratings are surveys of what our community members think about Akcea Therapeutics and other stocks. Vote "Outperform" if you believe AKCA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AKCA will underperform the S&P 500 over the long term. You may vote once every thirty days.
